Karen L. Reckamp

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Resistance to Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

  Journal of Clinical Oncology · 2026-06-03

• Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC).

  Journal of Clinical Oncology · 2026-05-28

• A randomized phase II study of capmatinib plus osimertinib with or without ramucirumab in patients with <i>EGFR</i> -mutant, <i>MET</i> -amplified stage IV or recurrent no–small cell lung cancer (Lung-MAP Sub-Study S1900G).

  Journal of Clinical Oncology · 2026-05-28

• A phase II study of amivantamab hyaluronidase in <i>MET</i> amplification–positive stage IV or recurrent non–small cell lung cancer (Lung-MAP Sub-Study).

  Journal of Clinical Oncology · 2026-05-28

• Immune-related adverse event severity and clinical outcomes with immune checkpoint inhibitor immunotherapy in participants with non–small cell lung cancer: Analysis of the lung MAP sub-studies S1400A, S1400I, S1400F, and S1800A.

  Journal of Clinical Oncology · 2026-05-28

• Factors associated with early cachexia in metastatic NSCLC: A nationwide Veterans Health Administration analysis.

  Journal of Clinical Oncology · 2026-05-28

• Support of academic non-clinical efforts for cancer investigator faculty at Association of American Cancer Institutes.

  Journal of Clinical Oncology · 2026-05-28

• Machine learning approach for prediction of immune-related pneumonitis.

  Journal of Clinical Oncology · 2026-05-27

• PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes

  Cancer Treatment Reviews · 2026-05-25

• PP01.118: Phase 1b/2 trial of BNT324/DB-1311 (B7H3 ADC) with Pumitamig (BNT327; PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC): BNT324-01 Trial in Progress

  Journal of Thoracic Oncology · 2026-05-01

• Anakinra prophylaxis for recurrent severe ICANS associated with tarlatamab in small cell lung cancer: Case Report

  JTO Clinical and Research Reports · 2026-05-01

• Xenium and IMC data for revealing the resistance of immune checkpoint inhibitors in NSCLC

  Zenodo (CERN European Organization for Nuclear Research) · 2026-04-30

• Xenium and IMC data for revealing the resistance of immune checkpoint inhibitors in NSCLC

  Zenodo (CERN European Organization for Nuclear Research) · 2026-04-30

• Abstract CT140: Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)

  Cancer Research · 2026-04-17

• Abstract 2479: Embedding community voices in clinical research: The value of community scientists in IIT protocol review

  Cancer Research · 2026-04-03

• Abstract 3999: Pan-cancer prediction of response to immune checkpoint blockade from histopathology

  Cancer Research · 2026-04-03

• Abstract 3928: Dynamic inflammatory biomarkers are associated with cancer cachexia in a prospective lung cancer cohort.

  Cancer Research · 2026-04-03

• Abstract 2434: Prognostic and predictive effects of <i>TP53</i> co-mutations and <i>RET</i> fusion partners in <i>RET</i> -rearranged advanced NSCLC

  Cancer Research · 2026-04-03

• Xenium and IMC data in "Spatial Single-Cell Profiling Identifies Immune-Cold Tumor Niches Linked to Early Progression on EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant NSCLC"

  Zenodo (CERN European Organization for Nuclear Research) · 2026-03-31

• Xenium and IMC data in "Spatial Single-Cell Profiling Identifies Immune-Cold Tumor Niches Linked to Early Progression on EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant NSCLC"

  Zenodo (CERN European Organization for Nuclear Research) · 2026-03-31